|Articles|September 1, 2004
- Pharmaceutical Executive-09-01-2004
September Table of Contents
September Table of Contents
Advertisement
Articles in this issue
over 21 years ago
September Table of Contentsover 21 years ago
(Huge) Untapped Opportunityover 21 years ago
Information Into Actionover 21 years ago
Halting the Hypeover 21 years ago
Spend Trends: A $20 Billion Bill and Plenty of Changeover 21 years ago
From the Mouths of Babesover 21 years ago
Safe and Secureover 21 years ago
Synta's Surpriseover 21 years ago
The New Building Blocks for Blockbustersover 21 years ago
Specialty Therapies Lose Special StatusAdvertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
FDA Makes Leadership Overhaul Following Commissioner Makary’s Departure: Report
2
Regeneron Enters $2.3 Billion Collaboration with Parabilis Medicines to Discover & Develop Multiple Therapeutic Candidates
3
The Risks and Benefits of FDA Reviewing Real-Time Data
4
FDA Approves Baxdrostat for Uncontrolled Hypertension in First-in-Class Entry
5